AMYRIS : Signs Contract Manufacturing Agreement with Tate & Lyle
11/04/2010| 03:10pm US/Eastern
Recommend:
Amyris, Inc. (NASDAQ:AMRS) announced today that it has entered into a
contract manufacturing agreement with Tate & Lyle Ingredients Americas,
Inc., an affiliate of Tate & Lyle PLC (LSE:TATE). Under this
arrangement, Tate & Lyle will produce farnesene at its facilities in
Decatur, IL; the produced farnesene will be owned and distributed by
Amyris.
This arrangement with Tate & Lyle expands Amyris's contracted production
capacity. Amyris entered into a similar agreement in June 2010 with a
facility of Biomin GMBH in Piracicaba, Brazil. Amyris expects to begin
production of farnesene at the Biomin facility in the first half of 2011.
Amyris is using contract manufacturing capacity to produce farnesene at
commercial scale to supply customer demand in advance of the start up of
Amyris's first commercial plant under its joint venture with Grupo São
Martinho (SA:SMTO3).
?We are excited to be collaborating with Tate & Lyle to accelerate our
commercial production of farnesene,? said John Melo, CEO of Amyris.
?Beyond supporting our commercial production targets in 2011, we believe
that this partnership will allow us to leverage Tate & Lyle's world
leading expertise in aseptic fermentation operations as we ramp our
industrial scale.?
?We are delighted to be working with Amyris to help them achieve the
first commercialization of its farnesene,? said Matt Wineinger,
President, Bulk Ingredients, Tate & Lyle. ?The combination of our
facilities and expertise and Amyris's fermentation processes and
equipment are a truly excellent fit.?
About Amyris
Amyris is building an integrated renewable products company by applying
industrial synthetic biology to genetically modify microorganisms to
serve as living factories. Amyris designs these microorganisms to
produce defined molecules for use as renewable chemicals and
transportation fuels. Amyris Brasil S.A., a subsidiary of Amyris,
oversees the establishment and expansion of Amyris's production in
Brazil, including SMA Indústria Química S.A., its joint venture with São
Martinho. In addition, Amyris is building fuels distribution
capabilities in the United States through its subsidiary, Amyris Fuels
LLC. More information about Amyris and its subsidiaries is available at www.amyris.com.
Forward-Looking Statements
This release may be deemed to contain forward-looking statements, which
are which are subject to safe harbor provisions under the Securities Act
of 1933, as amended, or the Securities Act, and the Securities Exchange
Act of 1934, as amended. All statements other than statements of
historical facts are statements that could be deemed forward-looking
statements. These forward-looking statements include, among other
things, statements regarding future events (such as statements regarding
Amyris's expectations for the commencement of production at the Tate &
Lyle and Biomin production facilities, customer demand for Amyris
products, benefits of the Tate & Lyle manufacturing arrangement,
including the ability to produce farnesene at commercial scale, and
timing for commercial production) that involve risks and uncertainties.
Readers are cautioned that these forward-looking statements are based on
management's current expectations and actual results and future events
may differ materially from those projected due to a variety of factors,
including: Amyris's limited operating history and lack of revenues
generated from the sale of its renewable products; Amyris's inability to
increase yield in yeast strains producing target molecules and decrease
production costs to enable sales at competitive prices; technical
infeasibility of engineering new target molecules; delays in production
and commercialization of products due to technical, operational, cost
and counterparty challenges; challenges in developing customer base in
markets with established and sophisticated competitors; currency
exchange rate and commodity price fluctuations; changes in regulatory
schemes governing genetically modified organisms and fuels; and other
factors detailed in Amyris's Securities and Exchange Commission filings,
including the risks identified under the section captioned ?Risk
Factors? in its final prospectus relating to its initial public offering
filed pursuant to Rule 424(b) under the Securities Act on September 28,
2010. Amyris disclaims any obligation to update information contained in
these forward-looking statements whether as a result of new information,
future events, or otherwise.
Amyris, Inc.
Erin Kinsella, 510-597-4713
pr@amyris.com
© Business Wire 2010
Recommend :
